Acid peptic diseases: pharmacological approach to treatment.
about
Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infantsThe management of gastro-oesophageal reflux diseaseAntisecretory, gastroprotective, antioxidant and anti-Helicobcter pylori activity of zerumbone from Zingiber zerumbet (L.) SmithNeurochemical Plasticity of the Coeliac-Superior Mesenteric Ganglion Complex Neurons Projecting to the Prepyloric Area of the Porcine Stomach following HyperacidityProphylactic effects of Clausena excavata Burum. f. leaf extract in ethanol-induced gastric ulcers.Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.The Effect of Marshallagia marshalli on Serum Gastrin Concentrations in Experimentally Infected Lambs.Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.Dosage effects of histamine-2 receptor antagonist on the primary prophylaxis of non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers: a retrospective cohort study.Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.Nebivolol prevents indomethacin-induced gastric ulcer in rats.Changes in Somatostatin-Like Immunoreactivity in the Sympathetic Neurons Projecting to the Prepyloric Area of the Porcine Stomach Induced by Selected Pathological Conditions.Insect tea attenuates hydrochloric acid and ethanol-induced mice acute gastric injury.Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats.In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.Gastroprotective Mechanism and Ulcer Resolution Effect of Cyrtocarpa procera Methanolic Extract on Ethanol-Induced Gastric Injury.Misoprostol decreases oxidative stress and liver injury in bacterial lipopolysaccharide-induced endotoxemia in mice
P2860
Q24186815-680F366A-8CCB-4753-8CA2-EDC521D1DBECQ26753012-B66C4365-0375-4391-AE87-E7226DD0A7A9Q28544881-AB5ADEA1-A062-45ED-AFAB-455D5C6CFFECQ36945717-600613CB-AB94-4A4A-9813-026F87ADFAE3Q37021487-A8E664E6-E9F6-4F95-BC9F-EE496B41673FQ37421468-C014E9BA-8AD6-4870-9BBF-AC1C458047D7Q38415822-8B21B414-3014-4EC3-9BC9-5F1F6A4D898AQ39746768-80FEE98A-00F5-47E7-BF82-7B8851E3F9B1Q39776157-625F25D1-A40F-4D85-98DF-39419233C8F1Q40608496-55B3E5C7-94DF-4AED-94A1-E1A36832B23AQ40672521-9B7B8A02-0A87-4A68-8A7F-90C157410AD0Q42023861-8C51E242-1744-45CB-B17F-8123DA5C1B3CQ44452482-CEFCEB73-3CD9-45B0-B639-CD1776B4E422Q45976996-E090AF61-DC9B-4386-ACEE-C443CB482301Q46891797-B5760438-B834-4206-9B0B-7BF0957DC273Q47099670-0D544F3C-6212-4E86-BCF4-05232B94543BQ47122744-3AD96786-7226-4402-8689-0E2D25F80B0DQ47225018-F56FECEB-03D2-4FAF-89C4-5829C8B58A08Q48099127-EA99A855-66FF-4E0D-B9DB-438B210688B8Q48339888-12E40028-DCBA-4694-9093-B1EBD8172BFDQ51315381-1C2A8AFA-F865-4426-8509-1BEAFB18CEC6Q51642470-10D8433A-B159-48F6-934B-2F9CFC6DBDC8Q51744141-D8D603CF-0796-4BA9-AE48-5E7DE9574FF1Q57729869-77136827-F577-4728-9A1F-67718608EDAF
P2860
Acid peptic diseases: pharmacological approach to treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Acid peptic diseases: pharmacological approach to treatment.
@en
Acid peptic diseases: pharmacological approach to treatment.
@nl
type
label
Acid peptic diseases: pharmacological approach to treatment.
@en
Acid peptic diseases: pharmacological approach to treatment.
@nl
prefLabel
Acid peptic diseases: pharmacological approach to treatment.
@en
Acid peptic diseases: pharmacological approach to treatment.
@nl
P2860
P356
P1476
Acid peptic diseases: pharmacological approach to treatment.
@en
P2093
Alex Mejia
P2860
P304
P356
10.1586/ECP.09.8
P407
P577
2009-05-01T00:00:00Z